Thursday, February 29, 2024

Tag: Oligodendrocyte Progenitor Cells

Asterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study

Ability to enroll patients with second most common cervical spinal cord injury broadens eligible population for SCiStar study and future trials FREMONT, Calif., July 10,...

Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at...

Third patient recovers two motor levels; three of six (50%) patients in AIS-A 10 million cell cohort have now recovered two motor levels on...

Generating improvement in spinal cord injuries

Early clinical trial results announced offer new hope in regenerative medicine A new therapy to treat spinal cord injuries in people who have lost all...

Stem Cells vs. Spinal Cord Injuries

A paralyzing injury to the neck during recreational activities such as horseback riding or playing football usually has permanent, lifelong effects that change a...

Stem cell trial for spinal cord injuries cleared by FDA

An experimental treatment using controversial embryonic stem cells to fix severe spinal cord injuries has new life under a new company. Asterias Biotherapeutics Inc. of...

What is the potential of Oligodendrocyte Progenitor Cells to successfully treat human spinal cord...

Spinal cord injury is a serious and debilitating condition, affecting millions of people worldwide. Long seen as a permanent injury, recent advances in stem...